

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 June 2003 (05.06.2003)

PCT


(10) International Publication Number
WO 03/045968 A1

- (51) International Patent Classification⁷: C07H 19/24, A61K 31/7052, A61P 37/02 (74) Agent: DAIGNAULT, Ronald, A.; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903 (US).
- (21) International Application Number: PCT/US02/38001 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 27 November 2002 (27.11.2002) (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/333,460 27 November 2001 (27.11.2001) US
- (71) Applicant: ANADYS PHARMACEUTICALS, INC. [US/US]; 9050 Camino Santa Fe, San Diego, CA 92121 (US).
- (72) Inventors: AVERETT, Devron, R.; 2529 Newport Avenue, Cardiff by the Sea, CA 92007 (US). WEBBER, Stephen, E.; 3531 Millikin Avenue, San Diego, CA 92122 (US).
- Published:
— with international search report

[Continued on next page]

(54) Title: 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-*d*]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Murine Interferon-alpha Response
Isatoribine 25 mg/kg i.v. vs Val-isatoribine 50 mg/kg p.o.



(57) Abstract: The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-*d*]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.